Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-04-16

Clinical Trial Update: Lenvatinib and Pembrolizumab Simultaneous Combination Study [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the combination of lenvatinib and pembrolizumab in advanced gastric cancer has completed, with results posted on 2025-04-16.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • KEYTRUDA (PEMBROLIZUMAB)
  • LENVIMA (lenvatinib)

Snippet

Sponsor: National Cancer Center Hospital East | Conditions: Advanced Gastric Cancer | Phase 2 | Status: COMPLETED | Results posted: 2025-04-16